- $7.62m
- -$9.14m
- 45
- 83
- 29
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.19 | ||
| Price to Tang. Book | 0.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.25% | ||
| Return on Equity | 19.37% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Apr | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Directors
- Kenneth Waggoner CHM (73)
- Carlos Trujillo CFO (63)
- Gerald Crabtree CSO (80)
- Walter Gunzburg CSO (61)
- Michael Abecassis IND (63)
- Thomas Liquard IND (48)
- Raymond Tong IND (62)
- Thomas Yuen IND (69)
- Last Annual
- April 30th, 2024
- Last Interim
- January 31st, 2025
- Incorporated
- October 28th, 1996
- Public Since
- September 11th, 2003
- No. of Shareholders
- 1,400
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 6,863,699
- Address
- 3960 Howard Hughes Parkway, Suite 500, LAS VEGAS, 89169
- Web
- https://pharmacyte.com/
- Phone
- +1 9175952850
- Auditors
- Marcum LLP
Upcoming Events for PMCB
Q1 2026 PharmaCyte Biotech Inc Earnings Release
Q2 2026 PharmaCyte Biotech Inc Earnings Release
Similar to PMCB
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Pharmacyte Biotech share price?
As of Today at 13:38 UTC, shares in Pharmacyte Biotech are trading at $1.11. This share price information is delayed by 15 minutes.
How has the Pharmacyte Biotech share price performed this year?
Shares in Pharmacyte Biotech last closed at $1.11 and the price had moved by -44.78% over the past 365 days. In terms of relative price strength the Pharmacyte Biotech share price has underperformed the S&P500 Index by -50.63% over the past year.
What are the analyst and broker recommendations for Pharmacyte Biotech?
The overall consensus recommendation for Pharmacyte Biotech is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pharmacyte Biotech dividend yield?
Pharmacyte Biotech does not currently pay a dividend.
Does Pharmacyte Biotech pay a dividend?
Pharmacyte Biotech does not currently pay a dividend.
When does Pharmacyte Biotech next pay dividends?
Pharmacyte Biotech does not currently pay a dividend.
How do I buy Pharmacyte Biotech shares?
To buy shares in Pharmacyte Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pharmacyte Biotech?
As of the previous close price of $1.11, shares in Pharmacyte Biotech had a market capitalisation of $7.62m.
Where are Pharmacyte Biotech shares listed?
Here are the trading details for Pharmacyte Biotech:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PMCB
What kind of share is Pharmacyte Biotech?
Based on an overall assessment of its quality, value and momentum Pharmacyte Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pharmacyte Biotech share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Pharmacyte Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmacyte Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -35.06%.
As of the last closing price of $1.11, shares in Pharmacyte Biotech were trading -26.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pharmacyte Biotech PE Ratio?
The Pharmacyte Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pharmacyte Biotech?
Pharmacyte Biotech's management team is headed by:
- Kenneth Waggoner - CHM
- Carlos Trujillo - CFO
- Gerald Crabtree - CSO
- Walter Gunzburg - CSO
- Michael Abecassis - IND
- Thomas Liquard - IND
- Raymond Tong - IND
- Thomas Yuen - IND